S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61

ContraFect Insider Trading & Ownership

-0.27 (-8.08%)
(As of 06/24/2022 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
85,400 shs
Average Volume
103,107 shs
Market Capitalization
$120.75 million
P/E Ratio
Dividend Yield
Price Target

ContraFect (NASDAQ:CFRX) Insider Buying and Selling Activity

Insider Ownership
Number Of
Insiders Buying
(Last 12 Months)
Number Of
Insiders Selling
(Last 12 Months)

CFRX Insider Buying and Selling by Quarter

Get CFRX Insider Trade Alerts

Want to know when executives and insiders are buying or selling ContraFect stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily.

ContraFect Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/13/2019Cary SucoffDirectorBuy50,000$0.39$19,500.0062,000  
12/13/2019Michael MessingerCFOBuy5,000$0.37$1,850.0019,091  
12/4/2018Fosun Pharmaceutical ShanghaiMajor ShareholderSell600,000$2.04$1,224,000.007,900,000  
7/25/2017Cara M CassinoInsiderBuy8,000$1.24$9,920.008,000  
7/25/2017Joshua B MuntnerSVPBuy2,000$1.24$2,480.002,000  
7/25/2017Sol J BarerDirectorBuy40,000$1.24$49,600.00815,933  
7/25/2017Steven C GilmanCEOBuy800$1.24$992.0020,800  
7/27/2016Steven C GilmanCEOBuy20,000$2.48$49,600.0020,000  
11/17/2015Daniel CoutoSVPSell2,872$3.81$10,942.32  
11/3/2015Daniel CoutoSVPSell2,867$4.23$12,127.412,872  
10/20/2015Daniel CoutoSVPSell2,867$4.48$12,844.165,739  
10/6/2015Daniel CoutoSVPSell2,867$4.11$11,783.378,606  
9/22/2015Daniel CoutoSVPSell2,867$4.76$13,646.9210,773  
9/8/2015Daniel CoutoSVPSell2,867$4.90$14,048.3014,340  
3/2/2015Julia P GregoryCEOBuy11,778$4.61$54,296.58  
(Data available from 1/1/2013 forward)

ContraFect Insider Trading - Frequently Asked Questions

Who is on ContraFect's Insider Roster?

The list of insiders at ContraFect includes Cary Sucoff, and Michael Messinger. Learn more on insiders at CFRX.

What percentage of ContraFect stock is owned by insiders?

3.60% of ContraFect stock is owned by insiders. Learn more on CFRX's insider holdings.

This page (NASDAQ:CFRX) was last updated on 6/27/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.